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Abstract 
BACKGROUND. Hydrocortisone treatment is widely used in septic shock though survival 
benefit has only been reported in patients remaining hypotensive after fluid and 
vasopressor resuscitation whose plasma cortisol fails to rise appropriately to corticotropin. 
This study assessed outcome effects of hydrocortisone in a general septic shock 
population. 
METHODS. Multicenter, randomized, double-blind, placebo-controlled trial of 50 mg 
intravenous hydrocortisone (or placebo) every 6 hours for 5 days, then tapered off over six 
days. The primary outcome was 28-day mortality in corticotropin nonresponders. 
RESULTS. Five hundred patients were recruited of whom 499 (251 hydrocortisone, 248 
placebo) were analyzable. Of these, 233 (46.7%) were corticotropin nonresponders (125 
hydrocortisone, 108 placebo). No difference in 28-day mortality was seen in 
nonresponders (39.2% hydrocortisone, 36.1% placebo; p=0.69), or responders (28.8% 
hydrocortisone, 28.7% placebo; p=1.00). Overall, 86/251 (34.3%) hydrocortisone and 
78/248 (31.5%) placebo patients died by 28 days (p=0.51). Hydrocortisone hastened the 
time to shock reversal in nonresponders (p =0.056), responders (p=0.0001) and all 
patients (p=0.0004). However, it failed to increase the proportion of patients with shock 
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reversal in the total population or either corticotropin subset. There were more episodes of 
superinfection including new sepsis or septic shock in the hydrocortisone group. Only 500 
rather than the projected 800 patients were enrolled because of slow recruitment, 
termination of funding and time expiry of the trial drug. 
CONCLUSIONS. Hydrocortisone failed to improve survival or shock reversal in a general 
septic shock population, either overall or in corticotropin-nonresponders, though it did 
hasten shock recovery. (ClinicalTrials.gov number, NCT00147004). 
Abstract word count- 250 
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Severe sepsis is a major worldwide cause of mortality and morbidity 1,2 Septic shock, 
the most severe manifestation, occurs in 2-20% of inpatients.3  Its incidence is rising 4 and 
a mortality of 33-61% is reported in the placebo group of recent multicenter trials. 5,6,7,8  
The use of corticosteroids as an adjunctive therapy has been controversial for 
decades. 9 After the Schumer study,10 high-dose, short-course glucocorticoids became 
accepted therapy. Subsequent studies, however, failed to confirm survival benefit with this 
regimen and suggested an increase in superinfection-related mortality.11-13 Recent studies 
using lower doses (200-300 mg per day) of hydrocortisone for longer durations reported 
earlier reversal of shock 14-18 and improved survival. 14,16 This was particularly apparent in 
nonresponders to corticotropin, the prognostic importance of which had been previously 
recognized in critical illness.19,20  Recent meta-analyses 21,22 , reviews 20 and guidelines 23 
have advocated the use of ‘low-dose’ hydrocortisone in septic shock. These 
recommendations were primarily based on a study of septic shock patients remaining 
hypotensive after at least one hour of resuscitation with fluids and vasopressors,16 in 
which survival benefit was seen in corticotropin nonresponders receiving hydrocortisone 
and fludrocortisone. The CORTICUS study evaluated the efficacy and safety of low-dose 
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hydrocortisone therapy in a broader septic shock population, in particular patients 
responding to corticotropin in whom benefit was unproven. 9  
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Methods 
Experimental design and study organization 
This was a multicenter, randomized, double-blind, placebo-controlled study. The 
protocol was approved by the Ethics Committees of the 52 participating intensive care 
units (ICUs). Patients were enrolled from March 2002 until November 30, 2005. An 
Independent Data Safety and Monitoring Board (DSMB) met after each of three interim 
analyses. At study end, a Clinical Evaluation Committee blindly assessed the 
appropriateness of anti-infective treatments.  
 
Patients 
Patients of 18 years of age or above and hospitalized in participating ICUs were 
prospectively enrolled in the study if they met all eligibility criteria (Supplementary 
Appendix Table 1). Inclusion criteria included: (1) Clinical evidence of infection, (2) 
Evidence of a systemic response to infection, (3) Evidence of shock within the previous 72 
hours defined by a systolic blood pressure (SBP) <90 mmHg despite adequate fluid 
replacement OR need for vasopressors for at least one hour, and hypoperfusion or organ 
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dysfunction attributable to sepsis, and (4) Informed consent according to local regulations. 
Notable exclusion criteria included underlying disease with a poor prognosis, moribund 
patients likely to die within 24 hours, immunosuppression and prior administration of 
corticosteroids. 
 
Randomization 
Randomization (1:1) was stratified by center in blocks of four using a computer 
random number generator list provided by a statistician not involved in eligibility 
determinations, treatment administration or outcome assessments. In each center, study 
medication (hydrocortisone or placebo) sealed in sequentially numbered identical boxes 
contained the entire treatment for each patient to be administered sequentially. The 
sequence was concealed to investigators. All patients, medical and nursing staffs, 
pharmacists, investigators and members of the DSMB remained blinded throughout the 
study period. 
 
Treatments 
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Hydrocortisone was prepared (Rotexmedica, Trittau, Germany) in vials containing 
100 mg of hydrocortisone hemisuccinate powder with ampoules containing 2 ml of sterile 
water diluent and then coded and blinded centrally (Klocke Verpackungs-Service GmbH, 
Weingarten, Germany). Placebo was indiscernible from active treatment. Study drug was 
administered as a 50 mg intravenous bolus every six hours for 5 days, then tapered to 50 
mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and 
then stopped. A total of 29 doses were given. Evidence-based guidelines for patient 
management were encouraged. 24 
 
Definitions  
Organ system failure was defined for each of the 6 major organ systems as a 
Sequential Organ Failure Assessment (SOFA) score of 3 or 4 points. 25 Reversal of shock 
was defined as the maintenance of a SBP ≥90 mmHg without vasopressor support for ≥24 
hours.  Superinfection was defined as a new infection occurring ≥48 hours after study 
medication commenced. 26 New sepsis was defined as a new septic episode with or 
without microbiological confirmation. New septic shock was defined as a new septic shock 
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episode after reversal of the initial septic shock. Nonresponders to the corticotropin test 
were defined by a cortisol increase ≤9 µg/dl (248 nmol/l). 16  
 
Data collection at inclusion 
Clinical evaluation. The following data were recorded: 1) general characteristics including 
demographics, diagnoses and recent surgery, 2) severity of illness assessed by vital 
signs, Simplified Acute Physiology Score (SAPS) II, 27 and SOFA score, 25 and 3) 
interventions including type and doses of vasopressors, antibiotics and adjunctive 
treatment such as corticosteroids and etomidate. 
Laboratory variables. Hematological and chemistry data, blood gas determinations, and 
cultures of blood and other specimens drawn from potential sites of infection were 
recorded. A short corticotropin test was performed using blood samples taken immediately 
before and 60 minutes after an intravenous bolus of 0.25 mg tetracosactrin (Novartis, 
Nuremberg, Germany or Alliance, Chippenham, UK). After centrifugation, serum samples 
were stored at -20°C or below until assayed. To red uce heterogeneity in cortisol 
determination, all samples were measured blindly and serially before interim and final 
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analyses in a central laboratory using the ELECSYS Cortisol assay® (Roche Diagnostics, 
Mannheim/Penzberg, Germany).  
 
Follow-up 
During the 28-day period post-randomization, data were collected for vital signs, 
results from laboratory tests and cultures of specimens drawn from any new site of 
infection and any major interventions performed. Mortality at 28 days, discharge from ICU, 
hospital and at one year after randomization were recorded. 
 
Endpoints 
The primary endpoint was 28-day mortality in nonresponders to the corticotropin test.  
Secondary endpoints determined a priori were (i) 28-day mortality in responders to 
corticotropin and in all patients, (ii) ICU, hospital and one-year mortality, (iii) organ system 
failure reversal including shock, and (iv) ICU and hospital stay. 
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Safety was assessed by recording adverse events particularly superinfection, 
gastrointestinal bleeding, hyperglycemia, hypernatremia, clinical muscular weakness, 
stroke, acute myocardial infarction and peripheral ischemia.  
Methods to enhance quality of measurements included biannual investigator 
meetings, newsletters and random quality assurance evaluations. 
 
Statistical methods 
A sample size of 800 (400 patients per group) was needed to achieve 80% statistical 
power to detect an absolute decrease in mortality of 10% from an existing mortality rate of 
50% in the corticotropin nonresponder group (40% in the total group).  
All analyses were performed according to a pre-established plan. The population 
was analyzed by an “intention to treat” principle. Twenty-eight day all-cause mortality was 
analyzed by the Fisher’s exact test for differences between treatment groups. A maximum 
overall two-sided probability of a type-I error of 5% was accepted. The test result was 
corrected for two interim analyses for efficacy. Splitting the alpha error function was 
performed according to the method of O'Brian and Flemming (p=0.0006, p=0.005 and 
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p=0.047 for the first, second and final analysis, respectively). Twenty-eight day mortality 
was significantly different if the stopping criteria of the interim analysis were met or the 
two-sided p value of the final analysis was <0.047. All other secondary efficacy variables 
were assumed to be significantly different for p-values <0.05. Cumulative survival Kaplan-
Meier curves during the 28-day observation period were constructed and compared using 
the log-rank test. Median time to reversal of septic shock was calculated by Kaplan-Meier 
analysis. Adverse events were reported for the per protocol population. Multivariate 
analyses of the 28-day mortality were carried out by logistic regression models. 
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Results 
 
Study patients 
Five hundred patients were enrolled (Figure 1).  One patient in the hydrocortisone 
group was excluded because consent was withdrawn.  Of the remaining 499 patients, all 
patients met entry criteria though 15 fulfilled exclusion criteria (8 hydrocortisone, 7 placebo 
patients) as 14 had received previous steroids and one had undergone prior CPR. Eighty-
seven percent of both placebo and active groups received ≥90% of study drug. 
There were 233 (46.7%) corticotropin nonresponders (hydrocortisone 125; placebo 
108) and 254 (50.9%) responders (hydrocortisone 118; placebo 136). Results were 
unknown in 12 (2.4%) patients (hydrocortisone 8; placebo 4). Etomidate was used in 51 
(20%) hydrocortisone and 45 (18%) placebo patients before study entry, and in 22 (9%) 
and 20 (8%) after study enrollment. More of the patients receiving etomidate were 
nonresponders [58/96 (60%) versus 175/403 (43%)]. The median time between the last 
dose of etomidate and enrollment was 14 (range:1-67) hours.  
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At baseline, the two groups were well balanced for demographics (Table 1), clinical 
characteristics (Table 2), and the type and site of infection and infecting organisms 
(Supplementary Appendix Table 2). 
 
Main Outcomes   
Mortality 
The primary outcome of 28-day mortality in corticotropin nonresponders revealed no 
difference between the hydrocortisone [49 deaths (39.2%; 95% CI: 30.5-47.9%)] and 
placebo [39 deaths (36.1%; 95% CI: 26.9-45.3%)] groups. Likewise, no difference was 
seen in 28-day mortality in corticotropin responders with 34 (28.8%; 95% CI: 20.6-37.0%) 
and 39 (28.7%; 95% CI:21.1-36.3%) deaths in the hydrocortisone and placebo groups, 
respectively. Overall, there were 86 deaths (34.3%; 95% CI: 28.3-40.2%) in the 
hydrocortisone group and 78 deaths (31.5%; 95% CI: 25.6-37.3%) in the placebo group.  
No mortality differences were seen between groups (or in responder/nonresponder 
subsets) at any other time point. Kaplan Meier survival curves are shown in Figures 2a-c 
and odds ratio and 95% confidence intervals in Table 3. Post hoc analysis showed a 
mortality rate of 31/69 (45%) in steroid-treated patients vs. 32/57 (56%) in placebo 
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patients (difference –11% (95% CI: -18.6 to 6.2%), p=0.28) with SBP persisting <90 
mmHg within 30 hours of study entry, and 55/181 (30%) in steroid-treated vs. 46/189 
(24%) in placebo patients (difference 6% (95%CI: -3.0 to 15.1%), p=0.20) with SBP >90 
mmHg within 30 hours of study entry. Post hoc analysis of the 198 patients receiving study 
drug within 12 hours from baseline, demonstrated a similar mortality rate of 71/198 (36%) 
in steroid-treated patients vs. 57/186 (31%) in placebo patients. 
 A post-hoc analysis revealed a trend to increased mortality in patients who received 
etomidate pre-randomization in both groups [23/51 (45%) hydrocortisone vs. 18/45 (40%) 
placebo] vs. not receiving etomidate [63/200 (32%) hydrocortisone vs. 60/203 (30%) 
placebo]. A logistic regression model adjusting for the treatment group (steroid/placebo), 
response to corticotropin (responder/non-responder), cortisol-baseline value (as 
continuous variable) and SAPS II Score revealed a p-value of 0.053 for the effect of 
etomidate. 
 
 
Reversal of shock  
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The proportion of shock reversal was similar for nonresponders [95/125 (76.0%; 95% 
CI: 68.5-83.5%) hydrocortisone, 76/108 (70.4%; 95% CI: 61.8-79.0%) placebo, p = 0.41]; 
responders [100/118 (84.7%; 95% CI: 78.3-91.2%) hydrocortisone, 104/136 (76.5%; 95% 
CI: 69.3-83.6%) placebo, p = 0.13]; or all patients [200/251 (79.7%; 95% CI: 74.7-84.7%) 
hydrocortisone, 184/248 (74.2%; 95% CI: 68.7-79.6%) placebo, p = 0.18]. Differences in 
shock reversal between hydrocortisone and placebo groups with relative risks (95% CI) for 
nonresponders, responders and all patients respectively, were 5.6% -5.8-17.0%) and 1.08 
(0.92-1.26), 8.3% -1.4-17.9%) and 1.11 (0.98-1.25), 5.5% (-1.9-12.9%) and 1.07 (0.98-
1.18) in favor of hydrocortisone.Time to shock reversal was significantly shorter in patients 
receiving hydrocortisone, for the overall group (p=0.0004), responders (p=0.0001) and 
nonresponders (p=0.0.056) (Figures 3a-c). The median time (95% CI) to shock reversal 
was shorter in the hydrocortisone group: for all patients 3.3 days (2.9-3.9) vs. 5.8 days 
(5.2-6.9); responders 2.8 days (2.1-3.3) vs. 5.8 days (5.2-6.9); and nonresponders 3. 9 
days (3.0-5.2) vs. 6.0 days (4.9-9.0).  
The number of extubated patients on day 28 was similar in the hydrocortisone and 
placebo groups, [119 (52%) vs. 113 (53%), respectively]. For the 357 patients with 
cultured pathogens for their primary infection, the Clinical Evaluation Committee's 
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determined appropriate antimicrobial therapy for 126 of 173 (73%) steroid and 145 of 184 
(79%) placebo treated patients. There was no difference between treatment groups nor 
outcome differences between patients receiving appropriate or inappropriate antibiotic 
therapy. 
 
useand other drug  Steroid 
Eleven patients (4%) in the hydrocortisone group and 10 (4%) in the placebo group 
received steroids after study enrollment for allergic reactions, laryngeal edema, 
bronchospasm, brain edema, steroid replacement for chronic steroid therapy unknown at 
enrollment, acute respiratory distress syndrome and septic shock. Five patients received 
steroids for septic shock after completion of the study drug course. The number of 
patients receiving activated protein C and antithrombin III was not different in the two 
groups (Table 2).  
 
Adverse events 
There was an increased incidence of superinfections including new episodes of 
sepsis or septic shock [odds ratios (95% CI) of 1.37 (1.05-1.79)], hyperglycemia and 
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hypernatremia in the hydrocortisone group (Table 4). Neuromuscular weakness was rarely 
reported.  
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Discussion 
This study found no impact of ‘low-dose’ hydrocortisone on 28-day mortality in septic 
shock patients, regardless of their adrenal responsiveness to corticotropin. Hydrocortisone 
did not significantly affect overall shock reversal but it did hasten the time to shock 
reversal. 
These results are in marked contrast to the Annane study 16 where improved survival 
and shock reversal were reported in corticotropin nonresponders receiving hydrocortisone 
plus fludrocortisone. Differences may relate to (i) dissimilar patient populations - the 
Annane patients had higher SAPS II scores at baseline, an entry requirement of SBP <90 
mmHg for >1 hour despite fluid and vasopressor therapy, and a much higher 28-day 
mortality in the placebo group (61% vs. 32% in CORTICUS); (ii) enrollment was only 
allowed within 8 hours of fulfilling entry criteria rather than the 72 hour window in 
CORTICUS; and (iii) fludrocortisone was not given in CORTICUS as 200mg 
hydrocortisone should provide adequate mineralocorticoid activity.28  Furthermore, 
absorption of oral fludrocortisone is variable in the shock state. Although an analysis of 
patients with SBP persisting <90 mmHg at day 1 after fluid and vasopressor resuscitation 
showed a placebo mortality of 56% and an absolute reduction in mortality of 11% in the 
 22
hydrocortisone group, similar to that reported by Annane, 16 the subsets receiving study 
drug within 12 hours from baseline did not demonstrate any outcome differences. 
As reported previously, 14,15,18 a decrease in time to shock reversal with 
hydrocortisone was found in this study. However, the total number of patients achieving 
shock reversal was unaffected. It remains unclear why vascular tone improves in some 
patients but not others. Unexpectedly, earlier shock reversal was greater in corticotropin 
responders but was not associated either with survival benefit or reduction in duration of 
ICU or hospital stay. These findings may be unrelated to adrenal insufficiency but could 
instead result from a direct interaction with mechanisms producing vascular hyporeactivity. 
29,30
 Alternatively, the effect may be due to a more widespread anti-inflammatory action of 
glucocorticoids, inhibiting expression of pro-inflammatory cytokines, mediators and 
receptors. 31   
The duration of steroid dosage may be pertinent, with any gain achieved by earlier 
shock reversal counterbalanced by later complications.9 Annane stopped corticosteroid 
treatment abruptly after 7 days whereas, in CORTICUS, therapy was tapered from day 5 
to day 11. Tapering was used because of the increase in pro-inflammatory mediators and 
hemodynamic deterioration after abrupt cessation of steroids. 17 The present study found 
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an increased incidence of superinfections including new episodes of sepsis or septic 
shock in the hydrocortisone group. Previous studies with high dose steroids have shown 
similar findings.11  Interestingly, the ARDSnet study using higher dose steroids  32  and 
meta-analyses of studies with low doses 21,22 did not report higher rates of infectious 
complications.  
Studies in the critically ill have reported an association between steroid therapy and 
the incidence of neuromuscular weakness. 32,33 This was not seen in CORTICUS although 
electrophysiological testing was not performed. The duration of mechanical ventilation 
was, however, similar in the two groups. Finally, the increased glucose levels in the 
hydrocortisone group may have contributed to an increased mortality. 34  
The use of etomidate for induction of anesthesia was similar to the Annane study16 
(24% vs. 23% in CORTICUS). Etomidate has a low cardiovascular complication profile 35 
but a single dose can inhibit steroid metabolism for at least 24 hours in the critically ill. 36 
An association between etomidate and the likelihood of adrenal hyporesponsiveness was 
also found in this study. 
The prognostic importance of adrenal insufficiency in septic shock is well 
described.19 Routine testing of adrenal function has been advocated to guide steroid 
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therapy. 16,18-21  In the present study a modest increase in 28-day mortality was seen in 
corticotropin nonresponders (38% vs 29% in responders) but there was no outcome 
difference with hydrocortisone treatment in either subset. The short corticotropin test does 
not appear useful for determining steroid treatment in septic shock and the results 
question the definition of relative adrenal insufficiency. Indeed, significant variability in 
cortisol levels has been described depending on the measurement methodology used. 37  
Recent studies have described the poor relationship between total and free cortisol levels 
38 and other issues concerning the dose, timing and type of corticotropin. 39   
Strengths of the present study include the fact that it was a European-wide, 
investigator-initiated study including 52 ICUs from 9 countries. Practically all the 
CONSORT requirements for reporting randomized trials were met a central laboratory was 
used for measuring cortisol and quality assurance evaluations revealed few problems. 
Limitations of the study include the lack of adequate power as only 500 patients were 
enrolled rather than the projected 800. This was due to a combination of slow recruitment 
likely related to a loss of equipoise in view of the various guidelines recommending steroid 
use, 23 termination of funding, and time expiry of the trial drug. Based on the current data, 
however, the likelihood of seeing any difference in outcomes between the two groups was 
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unlikely. Finally, 21 (4%) patients received open-label steroids though this is unlikely to 
have materially affected the outcome.  
In summary, hydrocortisone did not decrease mortality in a general septic shock 
population despite hastening shock reversal. This lack of improvement may be related to 
an increased incidence of superinfections and new septic episodes. No benefit was seen 
in the corticotropin nonresponder subgroup, as was shown previously for patients with 
severe septic shock. This may be related to methodological issues surrounding the 
accurate diagnosis of adrenal insufficiency in the critically ill or to a decreased prognostic 
importance of this phenomenon in less severe shock. The short corticotropin test is not 
useful in guiding steroid therapy. On the basis of these findings, hydrocortisone cannot be 
recommended as general adjuvant therapy for septic shock (vasopressor responsive), nor 
can corticotropin testing to determine who should receive it. Hydrocortisone may have a 
role in patients treated early after the onset of septic shock who remain hypotensive 
despite high dose vasopressors (vasopressor unresponsive). 16    
 
 26
References 
1.  Angus DC, Linde-Zwirble, W, Lidicker J, Clermont G, Carcillo J, Pinsky, M. 
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, 
and associated costs of care. Crit Care Med 2001;29:1303-1310.  
2.  Moreno R, Afonso S, Fevereiro T. Incidence of sepsis in hospitalized patients. 
Current Infectious Disease Reports 2006;8:346-50. 
3.   Matot I, Sprung CL.  Definition of sepsis.  Sprung CL, Bernard GR, Dellinger RP 
(Editors).  In: Guidelines for the management of severe sepsis and septic shock.  
Intensive Care Med 2001;27:S1-S9. 
4.  Annane D, Aegertner P, Jars-Guincestre MC, Guidet B. Current epidemiology of 
septic shock. The CUB-Rea network. Am J Resp Crit Care Med 2003;168:165-172. 
5.  Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 
2003;31:946-955. 
6.  Warren BL, Eid A, Singer P, et al. High-dose antihrombin III in severe sepsis. A 
randomized controlled trial. JAMA 2001;286:1869-1878. 
 27
7.  Abraham E, Reinhart K, Opal S, et al. Efficiacy and safety of tifacogin (recombinant 
tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA 
2003;290:238-247. 
8.  Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in 
subgroups of the recombinant human activated protein C worldwide evaluation in 
severe sepsis (PROWESS) trial. Crit Care Med 2004;32:2207-2218. 
 9.  Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-1713. 
10. Schumer W.  Steroids in the treatment of clinical septic shock. Ann Surg 
1976;184:333-341. 
11.   Sprung CL, Caralis PV, Marcial EH, et al. 1984. The effects of high-dose 
corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J 
Med 1984;311:1137-1143. 
12.  Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a 
meta-analysis. Crit Care Med 1995;23:1294-1303. 
13. Cronin L, Cook DJ, Carlet J, et al.  Corticosteroid treatment for sepsis: A critical 
appraisal and meta-analysis of the literature. Crit Care Med 1995; 24:1430-1439. 
 28
14.   Bollaert PE, Charpentier C, Levy S et al. Reversal of late septic shock with 
supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50. 
15   Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse 
hyperdynamic septic shock: A prospective, randomized, double-blind, single center 
study. Crit Care Med 1999;27:723-32. 
16.   Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of 
hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 
2002;288:862-870. 
17.  Keh D,  Boehnke T, Weber-Carstens S, et al.  Immunologic and hemodynamic 
effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, 
placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-520. 
18.   Oppert M, Schindler R, Husung C, et al. Low dose hydrocortisone improves shock 
reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care 
Med 2005; 33:2457-2464. 
19.  Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellisant E. A 3-level 
prognostic classification in septic shock based on cortisol levels and cortisol 
response to corticotrophin. JAMA 2000;283:1038-1045. 
 29
20.  Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patient. N Engl J 
Med 2003;348:727-734. 
21.  Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and 
septic shock: a systematic review and meta-analysis. BMJ 2004;329:480-488. 
22.  Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: The effects of steroids on 
survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 
141:47-56. 
23.  Dellinger P, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for the 
management of severe sepsis and septic shock. Crit Care Med  2004;32:858-873. 
24.  Sprung CL, Bernard G, Dellinger RP. Guidelines for the management of severe 
sepsis and septic shock.  Intensive Care Med 2001;27:S128-S134. 
25.  Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the 
incidence of organ dysfunction/failure in intensive care units: Results of a 
multicentric, prospective study. Crit Care Med 1998;26:1793-1800. 
26.  Garner J, Jarvis WR, Emori TG, Horan T, Hughes, J. CDC definitions for nosocomial 
infections. Am J Infect Control 1988; 16:28-40. 
 30
27.  Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS 
II) based on a European/North American multicenter study. JAMA 1993;270:2957-
63. 
28. Axelrod L, Corticosteroid therapy. In: Becker KL (Ed). Principles and practice of 
endocrinology and metabolism. 3rd Edition. Lippincott, Williams & Wilkins. 
Philadelphia 2001, pp. 762-8 
29.  Silverman HJ, Penaranda R, Orens JB, et al: Impaired beta-adrenergic receptor 
stimulation of cyclic adenosine monophosphate in human septic shock: Association 
with myocardial hyporesponsivenes to catecholamines. Crit Care Med 1993; 21:31-
39  
30.  Saito T, Takanashi M, Gallagher E, et al: Corticosteroid effect on early beta-
adrenergic down-regulation during circuatory shock: Hemodynamic study and beta-
adrenergic receptor assay. Intensive Care Med 1995; 21:204-210  
31. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- 
and glucocorticoid receptor alpha- mediated mechanisms in the regulation of 
systemic and pulmonary inflammation during sepsis and acute respiratory distress 
 31
syndrome. Evidence for inflammation-induced target tissue resistance to 
glucocorticoids. Neuroimmunomodulation. 2005; 12:321-338 
32. ARDS clinical trials network. Efficacy and safety for persistent acute respiratory 
distress syndrome. N Engl J Med 2006;354:1671-1684. 
33.  De Jonghe B, Sharshar T, Lefaucheur JP et al. Paresis acquired in the intensive care 
unit: a prospective multicenter study. JAMA 2002;288:2859-2867. 
34.   Van den Berghe G, Wouters P, Weekers F, Verwaest C, et al. Intensive insulin 
therapy in critically ill patients. N Engl J Med 2001;345:1359-1367. 
35.  Reves JG, Glass PSA, Lubarsky DA, McEvoy MD. Intravenous Nonopioid Anesthetics 
In: Miller RD, ed. Miller's Anesthesia, 6th Ed, Philadelphia, Pa, Churchill Livingstone 
2005:317-378. 
36.  Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h 
after a single dose of etomidate. Anaesthesia 1999;54:861-867. 
37.  Cohen J, Ward G, Prins J, Jones M, Venkatesh B. Variability of cortisol asssays can 
confound the diagnosis of adrenal insufficiency in the critically ill population. Intensive 
Care Med 2006:32:1901-1905. 
 32
38. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in 
critically ill patients. N Engl J Med 2004:350:1629-1638.  
39.  Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations 
of current assessment methods. J Clin Endocrinol Metab. 2006;91:3725-45. 
 
 
 33
Table 1. Demographic characteristics of 499 septic shock patients at baseline. 
Characteristic Non Responders Responders All patients 
 
 
Hydrocortisone 
 (N = 125) 
Placebo       
 (N = 108) 
Hydrocortisone 
 (N = 118) 
Placebo       
 (N = 136) 
Hydrocortisone 
 (N = 251) 
Placebo       
 (N = 248) 
)yr( SD +mean , Age 63 ± 13 63 ± 15 62 ± 14 64 ± 16 63 ± 14 63 ± 15 
Sex  - Male 
       Female 
85 (68) 
40 (32) 
69 (64) 
39 (36) 
76 (64) 
42 (36) 
95 (70) 
41 (30) 
166 (66) 
85 (34) 
166 (67) 
82 (33) 
Race- Caucasian Ω 119 (95) 101 (94) 110 (93) 125 (92) 236 (94) 228 (92) 
Prior or pre-existing disease 
      
- Hypertension 48 (38) 37 (34) 39 (33) 60 (44) § 89 (36) 98 (40) § 
- Coronary Artery Disease 20 (16) 26 (24) 17 (14) 21 (15) § 37 (15) 47 (19) § 
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- Congestive Heart Failure 5 (4) 8 (7) 4 (3) 12 (9) § 10 (4) 20 (8) § 
- Neurological Disease 19 (15) 10 (9) 14 (12) 14 (10) § 33 (13) 25 (10) § 
- COPD  14 (11) 12 (11) 11 (9) 17 (13) § 27 (11) 29 (12) § 
 - Other pulmonary disorder  6 (5) 12 (11) 17 (14) 12 (9) § 23 (9) 24 (10) § 
 Cancer 27 (22) 21 (19) 18 (15) 16 (12) § 47 (19) 37 (15) § 
 Diabetes 22 (18) 19 (18) 28 (24) 37 (27) § 51 (20) 56 (23) § 
 Liver Disease 14 (11) 10 (9) 9 (8) 7 (5) § 23 (9) 17 (7) § 
Chronic renal failure 12 (10) 11 (10) 10 (9) 10 (7) § 22 (9) 21 (9) § 
Admission category 
 Medical 
 Emergency surgery 
 
39 (31) 
69 (55) 
 
35 (32) * 
63 (58) * 
 
37 (31) † 
66(56) † 
 
57 (42) * 
67 (49) * 
 
80 (32) † 
138 (55) † 
 
93 (38) † 
132 (55) † 
 35
 Elective surgery 17 (14) 9 (8) * 13 (11) † 11 (8) * 31 (12) † 21 (9) † 
Data are means±SD for continuous variables or numbers of patients (percentages) for categorical variables. 
COPD = chronic obstructive pulmonary disease 
*- 1 missing value, †  - 2 missing values, § - 3 missing values 
Ω- Race- was ascertained by health care personnel 
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Table 2. Clinical characteristics of 499 septic shock patients at baseline 
Characteristic Non Responders Responders All patients 
 
 
Hydrocortisone 
 (N = 125) 
Placebo       
 (N = 108) 
Hydrocortisone 
 (N = 118) 
Placebo       
 (N = 136) 
Hydrocortisone 
 (N = 251) 
Placebo       
 (N = 248) 
      Temperature (°C) 37.7 ± 1.6* 37.9 ± 1.6 38.0 ± 1.4† 38.1 ± 1.3* 37.9 ± 1.5§ 38.0 ± 1.4* 
      Heart rate (beats/min) 121 ± 24* 119 ± 23 116 ± 29§ 117 ± 26 119 ± 26 Ω 118 ± 25 
     Systolic blood pressure (mm Hg) 92 ± 22* 97 ± 25 94 ± 24† 95 ± 29 94 ± 23§ 95 ± 27 
      SAPS II 50.7 ± 17.8 49.0 ± 16.3 47.9 ± 18.0* 48.4 ± 16.9 49.5 ± 17.8* 48.6 ± 16.7 
      SOFA Score 11.0 ± 3.4 10.7 ± 3.4 10.3 ± 3.4 10.5 ± 2.9 10.6 ± 3.4 10.6 ± 3.2 
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      Leukocytes (x103/mm3) 15.8 ± 11.2Ω 13.8 ± 9.8† 14.3 ± 8.1 Ω 15.4 ± 9.8§ 14.9 ± 9.8α 14.7 ± 9.8‡ 
      Platelets (x103/mm3) 205 ± 131 Ω 200 ± 150†  218 ± 140 Ω 203 ± 119 Ω 218 ± 140α 203 ± 119¶  
      Glucose (mg/dl) 140 ± 65 α 126 ± 52¶ 139 ± 59¥ 146 ± 45§ 140 ± 65! 137 ± 50β 
      Arterial lactate (mmol/l) 4.6 ± 4.0θ 4.0 ± 3.9γ 3.1 ± 3.0γ 4.1 ± 4.0δ 3.9 ± 3.6†† 4.1 ± 4.1** 
      PaO2/FiO2 (mm Hg) 159 ± 89£ 161 ± 72γ 162 ± 82# 149 ± 73€ 162 ± 89 154 ± 73Ψ 
Cortisol (µg/dl) 
 - Before corticotrophin  
 - 60 minutes after corticotropin 
 - Response to corticotropin test 
 
30 ± 20 
33 ± 19 
3  ±4 
 
29 ± 19 
32 ± 18 
3 ± 4 
 
27 ± 19 
46 ± 22 
18 ± 11 
 
29 ± 21 
46 ± 23 
16 ± 6 
 
28 ± 20 α 
39 ± 22 α 
11 ± 11 α 
 
29 ± 20 Ω 
39 ± 22 Ω 
10 ± 8 Ω 
On vasopressor/inotrope at baseline 125 (100) 108 (100) 117 (99) 131 (96) 249 (99) 243 (98) 
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Vasopressor-** number, (percent of 
patients receiving drug), and maximum 
dose (µg/kg/min) 
- norepinephrine 
 
- epinephrine 
 
- dopamine 
 
 
 
 
116 (93) 
0.5 ± 0.5 
19 (15) 
0.8 ± 1.6 
10 (8) 
12.9 ± 9.6 
 
 
 
104 (96) 
0.5 ± 0.5 
9 (8) 
0.2 ± 0.1 
9 (8) 
7.1 ± 6.3 
 
 
 
103 (87) 
0.4 ± 0.7 
14 (12) 
0.3 ± 0.4 
16 (14) 
9.8 ± 6.1 
 
 
 
124 (91) 
0.4 ± 0.5  
13 (10) 
1.4 ± 3.3 
19 (14) 
8.3 ± 7.1 
 
 
 
224 (89) 
0.5 ± 0.6 
35 (14) 
0.6 ± 1. 2 
27 (11) 
10.4 ± 7.5 
 
 
 
231 (93) 
0.4 ± 0.5  
22 (9) 
0.9 ± 2.6  
29 (12) 
7.9 ± 6.6 
Ventilatory support at baseline 
      
 39
      Mechanical ventilation 113 (90) 99 (92) 108 (91) 110 (81) 228 (90) 212 (86) 
       Tidal Volume (ml/kg) 7.6 ± 2.1γ  7.5 ± 2.1#  7.6 ± 2.2π 7.7 ± 2.2π 7.7 ± 2.1 7.6 ± 2.1Ψ 
       FiO2 (%) 67 ± 25 α 64 ± 25 Ω 60 ± 24µ 63 ± 24ω 64 ± 25& 63 ± 24! 
       PEEP (cm H2O)  8 ± 4‡ 8 ± 3¥ 9 ± 4 β 9 ± 4 9 ± 4π 9 ± 4§ 
Activated protein C §§ 11(9) 13 (12) 6 (5) 7 (5) 17 (7) 20 (8) 
Antithrombin III §§ 24 (19) 17 (16) 15 (13) 19 (14) 40 (16) 36 (15) 
 
Data are shown as mean±SD for continuous variables or numbers of patients (percentages) for categorical variables. 
SAPS II - Simplified Acute Physiology Score II; scores range from 0- 163, with higher scores indicating greater severity. SOFA - Sequential-
related organ failure assessment; scores range from 0-24, with higher scores indicating greater organ system failure. PaO2 - arterial oxygen 
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pressure. FiO2 : inspired oxygen fraction. PEEP- positive end expiration pressure. Tidal volume and PEEP missing values from ventilated 
patients. ** 5 patients received vasopressin, 4 in the steroid group and 1 placebo patient. 
*-1 missing value, † - 2 missing values, §- 3 missing values, Ω- 4 missing values, ‡- 5 missing values, ¶- 6 missing values, ¥- 7 missing values, 
α - 8 missing values, β - 9 missing values, ω- 11 missing values, µ- 12 missing values, π- 13 missing values, γ - 14 missing values, !- 16 
missing values, €- 17 missing values, £- 18 missing values, # - 19 missing values, &-20 missing values, δ -22 missing values, θ - 23 missing 
values, Ψ- 32 missing values, **- 36 missing values, ††- 49 missing values, §§- patients may have received these drugs after baseline. 
Cortisol: 1µg/dL = 27.59 nmol/L; PaO2/FiO2 1 mm Hg= 7.5 kPa; Glucose 1 mg/dl = 0.0555 mmol/L 
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Table 3. Outcome in 499 septic shock patients 
 
Non responders P value Responders P value All patients P value 
 
HC 
(N = 125) 
Placebo   
(N = 108) 
 HC 
(N = 118) 
Placebo   
(N = 136) 
 HC 
(N = 251) 
Placebo   
(N = 248) 
 
28-day mortality 49 (39.2) 39 (36.1) 0.69 34 (28.8) 39 (28.7) 1.00 86 (34.3) 78 (31.5) 0.51 
RR differences 
Difference HC- Placebo 
1.09 (0.77-1.52) 
3.1% [-9.5 to 15.7%] 
 
1.00 (0.68-1.48) 
0.1% [-11.2 to 11.4%] 
 
1.09 (0.84-1.41) 
2.8% [-5.5 to 11.2%] 
 
ICU mortality 58 (46.4) 44 (40.7) 0.43 41 (34.7) 45 (33.3) * 0.89 102 (40.6) 89 (36.0) * 0.31 
RR differences 
Difference HC- Placebo 
1.14 (0.85-1.53) 
5.7% [-7.1 to 18.4%] 
 
1.04 (0.74-1.47) 
1.4% [-10.3 to 13.1%] 
 
1.13 (0.90-1.41) 
4.6% [-3.9 to 13.1%] 
 
 42
Hospital mortality 60 (48.0) 50 (46.3) 0.90 48 (40.7) 50 (37.6) § 0.70 111 (44.2) 100 (40.8) § 0.47 
RR differences 
Difference HC- Placebo 
1.04 (0.79-1.36) 
1.7% [-11.1 to 14.6%] 
 
1.08 (0.79-1.47) 
3.1% [-9.0 to 15.2%] 
 
1.08 (0.88-1.33) 
3.4% [-5.3 to 12.1%] 
 
1-year mortality 73 (58.9) * 60 (57.1)§ 0. 89 61 (55.0)¥ 67 (53.2)ω 0.80 137 (56.6)β 127 (54.0)π 0.58 
RR differences 1.03 (0.83-1.29) 
 
1.03 (0.82-1.31) 
 
1.05 (0.89-1.23) 
 
ICU Length of stay (days) 17 ± 19 17 ± 17 0.47 18 ± 22 19 ± 16* 0.26 19 ± 31 18 ± 17* 0.51 
Hospital Length of stay 
(days) 
29 ± 26 31 ± 27 0.82 36 ± 40 35 ± 43§ 0.68 34 ± 41 34 ± 37§ 0.47 
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 .Data are numbers of deaths (percentages) and odds (RR) ratios (95% confidence intervals). p-values for categorial variables: Fisher's exact 
test, p-values for continuous variables: Wilcoxon rank sum test. HC = hydrocortisone, ICU = intensive care unit. *-1 missing value, † - 2 missing 
values, §- 3 missing values, ¥- 7 missing values, β - 9 missing values, ω- 10 missing values, π- 13 missing values. 
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Table 4. Adverse events in 466 septic shock patients (Per protocol population)  
Event 
 
Hydrocortisone 
(N = 234) 
Placebo 
 (N = 232) 
RR differences 
1. Superinfections 78 (33) 61 (26)  1.27 (0.96-1.68) 
 - Catheter-related infection     3 (1)   3 (1) 0.99 (0.20-4.86) 
 - Lung infection  34 (15) 30 (13) 1.12 (0.71-1.77) 
 - Gastrointestinal infection  22 (9) 19 (8) 1.15 (0.64-2.06) 
 - Urinary tract infection  11 (5) 10 (4) 1.09 (0.47-2.52) 
 - Wound infection     9 (4)   7 (3) 1.27 (0.48-3.37) 
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 - Other infection  16 (7) 8 (3) 1.98 (0.87-4.54) 
- New Sepsis 6 (3) 2 (1) 2.97 (0.61-14.59) 
- New Septic shock 14 (6) 5 (2) 2.78 (1.02-7.58) 
2. Other adverse events 85 (34) 63 (25)  
 - Anastomotic leak 4 (2) 4 (2) 0.99 (0.25-3.92) 
 - Wound dehiscence 2 (1) 2 (1) 0.99 (0.14-6.98) 
- Repeat Shock  84 (34) 62 (25) 1.34 (1.01-1.77) 
 - Bleeding – Any 21 (9) 16 (7) 1.30 (0.70-2.43) 
 - Bleeding – Gastrointestinal  15 (6) 13 (6) 1.14 (0.56-2.35) 
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 - Critical illness polyneuropathy 2 (1) 4 (2) 0.50 (0.09-2.68) 
 - Multiple organ system failure 34 (15) 33 (14) 1.02 (0.66-1.59) 
 - Refractory shock 20 (9) 25 (11) 0.79 (0.45-1.39) 
 - Pulmonary 8 (3) 13 (6) 0.61 (0.26-1.44) 
 - Renal 7 (3) 6 (3) 1.16 (0.39-3.39) 
 - Neurologic 1 (0) 1 (0) 0.99 (0.06-15.76) 
 - Hyperglycemia (Glucose ≥150 mg/dl on any 
day between day 1 & day 7) 
186 (85) 161 (72) 1.18 (1.07-1.31) 
 - Hypernatremia – (Sodium ≥150 mEq/L on any 
day between day 1 & day 7) 
67 (29) 42 (18) 1.58 (1.13-2.22) 
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3. Possibly related to shock    
- Stroke  3 (1) 1 (0) 2.97 (0.31-28.39) 
- Acute myocardial infarction  14 (6) 13 (6) 1.24 (0.34-4.56) 
- Peripheral limb ischemia - 1 (0)  
Data shown as numbers (percentages) and odds (RR) ratios (95% confidence intervals).     
An individual patient can have more than one adverse event 
Glucose 150 mg/dl = 8.3 mmol/L 
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Figure legends: 
 
Figure 1.  Study enrollment and analysis. 
 
Figure 2. Kaplan Meier Curves for 28 day all cause mortality in (a) corticotropin 
nonresponders (b) corticotropin responders and (c) all patients 
 
Figure 3. Kaplan Meier Curves for time to reversal of shock in (a) corticotropin 
nonresponders (b) corticotropin responders and (c) all patients.  
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